All In Biotech

Drug Trial Radar · NCT03270553

A Study to Assess the Effect of Plazomicin on the Pharmacokinetics of Metformin

A Phase 1, Open Label, Randomized, 2-Period, 2-Treatment, Crossover Study to Assess the Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Oct 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Aug 31, 2017

Primary completion

Oct 7, 2017

Study completion Oct 7, 2017

Sponsor

Lead sponsor
Achaogen, Inc.Industry
Sponsor type
Industry
First posted
Sep 1, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, Phase 1, open label, randomized, two-sequence, two-period, crossover study to evaluate the drug-drug interaction potential between plazomicin and metformin in healthy subjects.

Conditions

  • Healthy Volunteers

Interventions

  • plazomicinDrug

    single intravenous dose

  • metforminDrug

    single oral dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics of metformin in plasmaTime frame: 9 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Site

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.